Buspirone Hydrochloride

Phase 3Small molecule

Teva

Buspirone Hydrochloride is one of 61 small molecule programs targeting Spinal Cord Injury. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Spinal Cord InjuryActive, not recruiting

ALSRecruiting

Spinal Cord InjuryPhase 2

Active, not recruiting

ALSPhase 3

Recruiting

Competition

Competitive Landscape

65 competitors in Spinal Cord Injury

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Approved

2 2

Cialis

Eli Lilly

Approved

1 3

Keppra

UCB

Approved

1 4

Lioresal

Calciferol

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 7

Botox

RRevance Therapeutics, Inc.

Approved

1 8

Xarelto

WWim Janssens

Approved

1 9

Spiriva

Andriol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Spinal Cord Injury

NCT04458324

Clinical

Trials by Indication[1]

Postmenopausal Women1 trial

Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems

Completed·EEmotional Brain NY Inc.·Phase 2·NCT01743235·207 enrolled

ALS1 trial

Buspirone for Weak or Absent Esophageal Peristalsis

Recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 4·NCT05629325·25 enrolled

Spinal Cord Injury1 trial

Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord Injury

Active, not recruiting·SSpaulding Rehabilitation Hospital·Phase 2·NCT04458324·70 enrolled

Shortness of Breath1 trial

Buspirone in Reducing Shortness of Breath in Patients With Cancer

Completed·UUniversity of Rochester·Phase 2/3·NCT00053846·432 enrolled

Unspecified2 trials

Buspirone Hydrochloride 30mg Tablets, Fasting

Completed· Teva logo

Teva·Phase 1·NCT00840606·70 enrolled

Buspirone Hydrochloride 30mg Tablets, Non-Fasting

Completed· Teva logo

Teva·Phase 1·NCT00840398·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Buspirone Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Buspirone Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Buspirone Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Teva

Buspirone Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Postmenopausal Women1 trial

ALS1 trial

Spinal Cord Injury1 trial

Shortness of Breath1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News